Allergan buys rights to AstraZeneca's IBD treatment drug for $250M: 3 notes

Allergan has bought the rights to develop and commercialize MEDI2070, according to Zacks.

MEDI2070 is an experimental Crohn's disease and ulcerative colitis drug developed by the London-based pharmaceutical company AstraZeneca.

Here's what you need to know:

1. Allergan paid $250 million upfront during this transaction.

2. Allergan has agreed to pay AstraZeneca additional payments of up to $1.27 billion, should the drug hit certain product development and sales milestones.

3. MEDI2070 is in a phase IIb study concerning Crohn's disease treatment. The drug is also ready to begin phase II trials for ulcerative colitis treatment.

More articles on gastroenterology and endoscopy:
Predictive overbooking maximizes endoscopy clinic scheduling: 5 study insights
GI societies advocate for increased coverage of CRC screening, treatment: 4 notes
What is the future of colorectal cancer screening? Still colonoscopy, says Dr. David A. Johnson

© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Webinars

Featured Whitepapers